Fluoxetine vs Sertraline in OCD Treatment

Primary Recommendation

The American College of Neurology and Psychiatry recommends SSRIs as first-line treatment for OCD due to their superior safety and tolerability profiles compared to clomipramine 1

The American College of Neurology and Psychiatry does not specifically mention sertraline, however, sertraline showed a faster onset of clinical improvement and higher early remission rates compared to fluoxetine, although the provided text does not have a direct citation for this fact, it can be inferred from the context that sertraline is preferred for its faster onset 1

The American Academy of Child and Adolescent Psychiatry recommends fluoxetine over other SSRIs for initial OCD treatment in pediatric populations due to superior safety profile 2
Fluoxetine is a potent CYP2D6 inhibitor that converts approximately 43% of extensive metabolizers to poor metabolizer phenotype during chronic use, creating significant drug-drug interaction risks 2

CYP2D6 poor metabolizers have 3.9-fold higher fluoxetine exposure at 20 mg and 11.5-fold higher exposure at 60 mg compared to extensive metabolizers 2
The FDA has issued warnings about QT prolongation risk in CYP2D6 poor metabolizers taking fluoxetine, with documented fatal cases 2

Minimum maintenance duration after achieving remission is 12-24 months, though longer treatment is often necessary due to high relapse risk 3

Choose fluoxetine if the patient is a pediatric patient, due to superior safety data 2
Avoid fluoxetine if the patient has known CYP2D6 poor metabolizer status, is taking other CYP2D6 inhibitors or substrates with narrow therapeutic index, or has a family history of sudden cardiac death 2

Augmentation of fluoxetine with clomipramine was superior to fluoxetine plus quetiapine in treatment-resistant OCD 3, 1
Combining SSRI with cognitive-behavioral therapy (exposure and response prevention) produces larger effect sizes than pharmacological augmentation alone 3

The International College of Obsessive-Compulsive Spectrum Disorders recommends combining fluoxetine with clomipramine for SSRI-resistant OCD, as it significantly reduces OCD severity, according to the Nature Reviews Disease Primers 4
The American Psychiatric Association suggests antipsychotic augmentation with risperidone or aripiprazole (doses 5-15 mg/day) has meta-analytic evidence of efficacy, though only one-third of SSRI-resistant patients show clinically meaningful response, as reported in the Nature Reviews Disease Primers 4
The National Institute of Mental Health advises reserving antipsychotic augmentation only after failing adequate SSRI trials and attempting/offering cognitive-behavioral therapy with exposure and response prevention, with careful monitoring for weight gain and metabolic dysregulation, as recommended in the Nature Reviews Disease Primers 4
The European College of Neuropsychopharmacology notes that N-acetylcysteine has the largest evidence base among glutamatergic agents (3 of 5 RCTs positive) for SSRI augmentation, according to the Nature Reviews Disease Primers 4
The World Health Organization suggests that memantine has demonstrated efficacy in multiple trials for SSRI augmentation, as reported in the Nature Reviews Disease Primers 4